Based on current best practices, as well as an identified need to better support non-dialysis patients with advanced CKD (eGFR less than15 mL/min), a number of changes were made this summer to the BC Renal Agency’s formularies and to policy concerning funding of medications by the agency. These include:
- Updating existing symptom management algorithms to reflect current evidence. This resulted in the addition of new medications with proven efficacy and the removal of others that did not have strong evidence or had evidence of harm.
- Extending BC Renal Agency funding of symptom management medications to include non-dialysis patients with advanced CKD (eGFR less than 15 mL/min).